Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Proton pump inhibitors: impact on glucose metabolism.

Boj-Carceller D.

Endocrine. 2013 Feb;43(1):22-32. doi: 10.1007/s12020-012-9755-3. Epub 2012 Aug 12. Review.

PMID:
22886351
2.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
3.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

4.

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.

González C, Beruto V, Keller G, Santoro S, Di Girolamo G.

Expert Opin Investig Drugs. 2006 Aug;15(8):887-95. Review.

PMID:
16859392
5.

Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

Gallwitz B.

Minerva Endocrinol. 2006 Jun;31(2):133-47. Review.

PMID:
16682937
6.

Protection of pancreatic beta-cells: is it feasible?

Bonora E.

Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):74-83. Review.

PMID:
18096375
7.

Liraglutide in the management of type 2 diabetes.

Wajcberg E, Amarah A.

Drug Des Devel Ther. 2010 Oct 22;4:279-90. doi: 10.2147/DDDT.S10180. Review.

8.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
9.

Fate of the beta-cell in the pathophysiology of type 2 diabetes.

Campbell RK.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S10-5. doi: 10.1331/JAPhA.2009.09076. Review.

PMID:
19801360
10.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
11.
12.

Therapeutic approaches to preserve islet mass in type 2 diabetes.

Baggio LL, Drucker DJ.

Annu Rev Med. 2006;57:265-81. Review.

PMID:
16409149
13.

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

Briones M, Bajaj M.

Expert Opin Pharmacother. 2006 Jun;7(8):1055-64. Review.

PMID:
16722815
14.

Investigational agents that protect pancreatic islet beta-cells from failure.

Aston-Mourney K, Proietto J, Andrikopoulos S.

Expert Opin Investig Drugs. 2005 Oct;14(10):1241-50. Review.

PMID:
16185166
15.

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

Gallwitz B.

Drugs Today (Barc). 2007 Nov;43(11):801-14. doi: 10.1358/dot.2007.43.11.1157620. Review.

PMID:
18174966
16.

Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

Gallwitz B.

Drugs Today (Barc). 2007 Jan;43(1):13-25. Review.

PMID:
17315049
17.

Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.

Knop FK, Holst JJ, Vilsbøll T.

IDrugs. 2008 Jul;11(7):497-501. Review.

PMID:
18600596
18.

The potential of incretin-based therapies in type 1 diabetes.

Suen CS, Burn P.

Drug Discov Today. 2012 Jan;17(1-2):89-95. doi: 10.1016/j.drudis.2011.08.017. Epub 2011 Sep 6. Review.

PMID:
21920456
19.

The effects of glucagon-like peptide-1 on the beta cell.

Vilsbøll T.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:11-8. doi: 10.1111/j.1463-1326.2009.01073.x. Review.

PMID:
19878257
20.

Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes.

Levetan CS, Pierce SM.

Endocr Pract. 2013 Mar-Apr;19(2):301-12. doi: 10.4158/EP12138.RA. Review.

PMID:
23186955

Supplemental Content

Support Center